Evidence map›Paper›PMID 32384521›Full record

ArticleMedicine2020

The effect of vitamin D supplementation on the progression of fibrosis in patients with chronic liver disease: A protocol for a systematic review and meta-analysis.

Tiantian Chen, Xiaohong Zuo, Shengju Wang, Penglong Yu, Jie Yuan, Shujun Wei, Jiayi Chen, Yue Sun, Yongxiang Gao, Xueping Li

Open access · goldAbstract read
In one paragraph

Article in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Tiantian ChenDepartment of Rheumatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072.
Xiaohong ZuoSchool of basic medical sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137.
Shengju WangDepartment of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072.
Penglong YuDepartment of Rheumatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072.
Jie YuanSchool of basic medical sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137.
Shujun WeiSchool of basic medical sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137.
Jiayi ChenDepartment of Rheumatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072.
Yue SunSchool of basic medical sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137.
Yongxiang GaoCollege of International Education of Chengdu University of Traditional Chinese Medicine, PR China.
Xueping LiSchool of basic medical sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137.
Chengdu University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatic fibrosis (HF) is the common pathological basis of chronic liver disease (CLD). Many data indicate that serum vitamin D (VD) levels in patients with liver fibrosis are significantly lower than those without liver fibrosis, and lower level of serum 1,25(OH)2D3 is also an independent risk factor for patients with liver fibrosis combined with other diseases. VD has the functions of anti-fibrosis, regulating cell proliferation and differentiation, anti-inflammatory, and immune regulation, Therefore, serum 1,25(OH)2D3 level may be negatively correlated with the progression of liver fibrosis. But there is absent convincing evidence-based medicine to confirm the efficacy of VD supplementation for CLD. Thus, we aimed to conduct this meta-analysis to summarize the efficacy of VD supplementation on the progression of fibrosis in patients with CLD.

methodsThe study only selects clinical randomized controlled trials of VD supplementation for CLD. We will search each database from the built-in until September 2020. The English literature mainly searches Cochrane Library, Pubmed, EMBASE, and Web of Science. While the Chinese literature comes from CNKI, CBM, VIP, and Wangfang database. Meanwhile, we will retrieve clinical trial registries and gray literature. Two researchers worked independently on literature selection, data extraction and quality assessment. The dichotomous data is represented by relative risk (RR), and the continuous is expressed by mean difference (MD) or standard mean difference (SMD), eventually the data is synthesized using a fixed effect model (FEM) or a random effect model (REM) depending on the heterogeneity. The serum VD level, hepatic function and serological indexes of hepatic fibrosis were evaluated as the main outcomes. While several secondary outcomes were also evaluated in this study. The statistical analysis of this Meta-analysis was conducted by RevMan software version 5.3.

resultsThis meta-analysis will further determine the beneficial efficacy of VD supplementation on the progression of fibrosis in patients with CLD.

conclusionThis study determines the positive efficacy of VD supplementation for CLD. ETHICS AND DISSEMINATION: This review is based solely on a secondary study of published literatures and does not require ethics committee approval. Its conclusion will be disseminated in conference papers, magazines or peer-reviewed journals. REGISTRATION NUMBER: INPLASY202040054.

Indexed as

Dietary SupplementsChronic DiseaseDisease ProgressionHumansLiver CirrhosisLiver DiseasesLiver Function TestsMeta-Analysis as TopicRandomized Controlled Trials as TopicResearch DesignRiskSystematic Reviews as TopicVitamin DVitamin D

Identifiers

PMID32384521
PMCPMC7220037
OpenAlexW3015456802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.